{
  "pmcid": "11004700",
  "sha256": "1679f50447f4b919920d89f05a6f6f6fe8d759a06b3778ad34846bc4aa1888f0",
  "timestamp_utc": "2025-11-09T15:14:02.218077+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.277857142857144,
    "reading_ease": 21.32250000000002,
    "word_count": 225
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "205 patients who underwent varicose vein treatment with either polidocanol foam sclerotherapy (57 patients, 90 legs) or conventional surgery (148 patients, 236 legs)."
      },
      "Intervention": {
        "score": 2,
        "evidence": "polidocanol foam sclerotherapy compared to conventional surgery"
      },
      "Objective": {
        "score": 1,
        "evidence": "This large sample-size study was designed to evaluate the outcomes of polidocanol foam sclerotherapy compared to conventional surgery based on an analysis of PROMs."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Patients were preoperatively assessed and re-evaluated 30 days after the procedure using the Venous Disease Severity Score (VCSS) and specific venous disease quality-of-life questionnaires (VEINES-QoL/Sym)."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "205 patients who underwent varicose vein treatment"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "57 patients, 90 legs) or conventional surgery (148 patients, 236 legs)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "surgery promoted greater improvements in VCSS (on average 4.02-points improvement, p < 0.001), VEINES-QoL (average 8-points improvement, p < 0.001), and VEINES-Sym (average 11.66 points improvement, p < 0.001)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  }
}